NCT05223088View on ClinicalTrials.gov

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2024

Conditions
ImmunotherapyGastrict Cancer
Interventions
DRUG

Tislelizumab

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.

DRUG

Apatinib Mesylate

Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.

DRUG

oxaliplatin

Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.

DRUG

Tegafur

Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.

Trial Locations (1)

Unknown

Fujian cancer hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter